---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Dosage"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Dosage. Topics: Dose levels in dose escalation, Maximum tolerated dose, Doses selected for dose expansion, Recommended phase 2 dose of 120 mg, and 14 further topics. 18 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/dosage"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Dosage

<a id="heading-2.1.2.10.1"></a>

## 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

### Dose levels in dose escalation

> “The initial dose cohort received a dose of palazestrant at 30 mg/day, followed by dose cohorts of 60, 90, 120, 150, 210, and 300 mg/day.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.10.1-2"></a>

### Maximum tolerated dose

> “Palazestrant doses of up to 300 mg/day resulted in no DLTs, and the MTD was not reached.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.10.1-3"></a>

### Doses selected for dose expansion

> “both the 60 mg/day and 120 mg/day doses were selected for further study in the dose-expansion phase (phase 1b)”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.10.1-4"></a>

### Recommended phase 2 dose of 120 mg

> “Based on the tolerable safety profile, favorable PK, and encouraging antitumor activity shown in the phase 1 portion of the study, the 120 mg/day dose was chosen as the RP2D.”
> “Limited data were available for patients treated with 90 mg palazestrant, as only 6 patients were enrolled during dose escalation.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.10.1-5"></a>

### Dose reductions during dose escalation

> “Six patients had dose reductions”
> “2 patients at 210 mg dose had reductions: 1 patient to 120 mg and 1 patient to 60 mg”
> “4 patients at 300 mg dose had reductions: 3 patients to 120 mg and 1 patient to 60 mg”

Source: [Patel et al. (2021)](https://olema.com/wp-content/uploads/2023/08/Olema_Final-SABCS-Poster_11.29.21.pdf)

<a id="topic-2.1.2.10.1-6"></a>

### Dose modification for neutropenia in the monotherapy study

> “these were managed with dose interruptions or discontinuations and/or with colony-stimulating factors, and following dose reductions, 3 patients were able to continue palazestrant with no further recurrences of neutropenia”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.10.1-7"></a>

### Reduced dose levels after grade 4 neutropenia

> “Of these patients, three had a dose interruption with recovery and subsequent dose reduction (two continued at 90 mg and one continued at 60 mg) without any recurrence, and three had dose discontinuation followed by recovery.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="topic-2.1.2.10.1-8"></a>

### Blood count monitoring and dose modification in ongoing studies

> “All ongoing studies with palazestrant include proactive monitoring of blood counts that is more frequent during first 6–8 weeks after initiation of palazestrant, with the possibility for dose reduction or interruption following the detection of grade 3 or 4 neutropenia.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.10.1-9"></a>

### OPERA-01 dose selection design

> “In Part 1, the dose-selection portion of the study, eligible participants were randomized 1:1:1 to receive oral palazestrant at a dose of 90 mg or 120 mg once daily (QD) or investigator’s choice of SOC ET”
> “The Independent Data Monitoring Committee recommended a 90-mg palazestrant QD dose based on the available safety, efficacy, patient-reported outcomes, and pharmacokinetic data from participants treated in Part 1.”
> “In Part 2, participants receive once-daily palazestrant (90 mg QD) or SOC ET as described in Part 1.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-2.1.2.10.1-10"></a>

### OPERA-01 registry dosing

> “Doses evaluated in the dose-selection part will be 120 mg once daily and 90 mg once daily.”

Source: [ClinicalTrials.gov NCT06016738](https://clinicaltrials.gov/study/NCT06016738)

<a id="topic-2.1.2.10.1-11"></a>

### Dose selected with the FDA for the phase 3 trials

> “today announced it has aligned with the U.S. Food and Drug Administration (FDA) to select 90 mg of palazestrant as the dose for Part 2 of the ongoing registrational Phase 3 OPERA-01 trial”
> “The FDA also selected 90 mg of palazestrant in combination with the approved dose of CDK4/6 inhibitor ribociclib for the pivotal Phase 3 OPERA-02 trial in frontline ER+/HER2- metastatic breast cancer.”

Source: [Olema Oncology dose selection announcement (2025)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-palazestrant-dose-selection-and-trial)

<a id="topic-2.1.2.10.1-12"></a>

### Phase 3 dose as monotherapy and with ribociclib

> “The phase 3 dose of palazestrant as monotherapy or in combination with ribociclib is 90 mg QD.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-2.1.2.10.1-13"></a>

### OPERA-02 registry dosing

> “Participants will be treated with palazestrant 90 mg once daily on a 4-week (28-day) cycle.”
> “Participants will be treated with ribociclib 600 mg once daily on Days 1-21 of a 4-week (28 day) cycle.”

Source: [ClinicalTrials.gov NCT07085767](https://clinicaltrials.gov/study/NCT07085767)

<a id="topic-2.1.2.10.1-14"></a>

### OPERA-02 dose rationale

> “This data supports the OPERA-02 study evaluating 90 mg once-daily palazestrant in combination with 600 mg ribociclib for the first-line treatment of ER+, HER2− ABC.”

Source: [Tolaney et al. (2026)](https://olema.com/wp-content/uploads/2026/05/ASCO-2026-OPERA-02-TiP-Poster_FINAL.pdf)

<a id="topic-2.1.2.10.1-15"></a>

### Dosing with palbociclib

> “Patients received 30, 60, 90, or 120 mg palazestrant QD plus 125 mg palbociclib PO QD on days 1–21 of each 28-day treatment cycle.”
> “Dose-expansion (ongoing) patients receive 120 mg palazestrant plus 125 mg palbociclib QD.”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="topic-2.1.2.10.1-16"></a>

### Dose reductions with palbociclib

> “No patients had dose reduction of palazestrant for neutropenia. Eleven patients had dose reduction of palbociclib for neutropenia.”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="topic-2.1.2.10.1-17"></a>

### Dosing with ribociclib in dose escalation

> “palazestrant at 30, 60, and 120 mg once daily plus ribociclib 600 mg once daily on days 1–21 of each 28-day treatment cycle (Figure 2). The RP2D of palazestrant was 120 mg in combination with ribociclib.”

Source: [Borges et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-003_12-5-23.pdf)

<a id="topic-2.1.2.10.1-18"></a>

### Dose reductions with ribociclib

> “2 patients had a dose reduction of palazestrant only; 1 due to nausea and 1 due to neutropenia”
> “8 patients had a dose reduction of both treatments; 23 patients had a dose reduction of ribociclib. The most common cause for dose reduction was neutropenia.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

Additional sources: [OP-1250-001 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/26/NCT04505826/Prot_000.pdf)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
